Showing results (191-200 of 223) with videos related to
Sort By:
Pageof 23
Neuro-Oncology|July 7, 2023
Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)Anne Laprie, Georges Noel, Leonor Chaltiel, et al.The Lancet. Oncology|March 8, 2021
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJoël Guigay, Anne Aupérin, Jérôme Fayette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2020
PD-1 Blockade in Anaplastic Thyroid CarcinomaJaume Capdevila, Lori J Wirth, Thomas Ernst, et al.Oncotarget|August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.European Journal of Cancer (Oxford, England : 1990)|April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumoursMarie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.EMBO Molecular Medicine|May 25, 2021
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage componentBenoit Thibault, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, et al.Journal for Immunotherapy of Cancer|August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burdenMichael Schenker, Mauricio Burotto, Martin Richardet, et al.JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.NPJ Precision Oncology|April 9, 2026
Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerAnna Salvioni, Marie Michelas, Mathilde Del, et al.Pageof 23